Bevacizumab (anti-VEGF)

製品コードA2006 別名: rhuMab VEGF, Avastin

For research use only.
Not for use in humans.

Bevacizumab (anti-VEGF, Avastin) is a humanized anti-VEGF monoclonal antibody which binds to and neutralizes all human VEGF-A isoforms and bioactive proteolytic fragments, MW:149 KD.

Bevacizumab (anti-VEGF)
サイズ 価格(税別)
1mg JPY 36100
5mg JPY 103800

代表番号: 03-5615-9297|電子メール:[email protected]
よく尋ねられる質問

文献中Selleckの製品使用例(20)

質量管理及び製品安全説明書

VEGFR阻害剤の選択性比較

生物活性

製品説明 Bevacizumab (anti-VEGF, Avastin) is a humanized anti-VEGF monoclonal antibody which binds to and neutralizes all human VEGF-A isoforms and bioactive proteolytic fragments, MW:149 KD.
同型 Human IgG1
ターゲット
VEGFR2 [4] VEGF-A [4] VEGF [1]
体外試験

Blocking VEGF with bevacizumab reduces the proangiogenic effect of affected fibroblasts in both the matrigel and direct coculture angiogenesis models.[1]

体内試験

The combinational treatment of AAV9-LECT2-shRNA and bevacizumab significantly improves the therapeutic effects on liver fibrosis.[2]

お薦めの試験操作(参考用のみ)

細胞試験:
  • Matrigel gels were created using low GF Matrigel (protein concentration > 9.5 mg/ml) in a 48-well plate. It was gelled at 37 ℃ overnight and then rinsed twice with PBS. endothelial cells (ECs) were added in 250 μl endothelial basal medium with no supplement and allowed to adhere for 1 hour. An additional 250 μl of 48 h conditioned medium from unaffected or affected fibroblasts or nonconditioned medium with or without 20 ng/ml VEGF and with or without 250 μl/ml bevacizumab in 5% FBS + 1% penicillin/streptomycin in DMEM was added, and ECs were incubated for 14 h before being fixed and stained for CD31. ECs network formation was also tracked by live-cell imaging at 2, 4, 8, 16, and 24 h.

動物試験:
  • Animal Models: Male C57BL/6J mice of CCl4-induced fibrosis model
    Dosages: 2 mg/kg
    Administration: i.p.
    Reference: https://pubmed.ncbi.nlm.nih.gov/34940991/
     

製品説明

CAS No. 216974-75-3
Formulation PBS buffer, pH 7.2
Isotype Human IgG1
Source CHO cells
Storage Store the undiluted solution at 4°C in the dark to avoid freeze-thaw cycles

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

* 必須

大学・企業名を記入してください
名前を記入してください
電子メール・アドレスを記入してください 有効なメールアドレスを入力してください
お問い合わせ内容をご入力ください

よくある質問(FAQ)

質問:1:
How to store the antibody?

回答:
Store the undiluted solution at 4 °C in the dark. Freezing antibodies can result in a loss of activity caused by the freezing/thawing process. Diluting antibodies to working concentrations and storing at 4°C for more than a day should be avoided. Additionally, make sure to keep the antibody sterile. Under these storage conditions, your antibodies should remain active for up to one year and oftentimes longer.

Tags: Bevacizumab (anti-VEGF)を買う | Bevacizumab (anti-VEGF) ic50 | Bevacizumab (anti-VEGF)供給者 | Bevacizumab (anti-VEGF)を購入する | Bevacizumab (anti-VEGF)費用 | Bevacizumab (anti-VEGF)生産者 | オーダーBevacizumab (anti-VEGF) | Bevacizumab (anti-VEGF)化学構造 | Bevacizumab (anti-VEGF)分子量 | Bevacizumab (anti-VEGF)代理店